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The present perspective paper addresses and discusses whether cognitive dysfunction
in bipolar disorder qualifies as a diagnostic intermediate phenotype using the Robin and
Guze criteria of diagnostic validity. The paper reviews current data within (1) delineation
of the clinical intermediate phenotype, (2) associations of the intermediate phenotype
with para-clinical data such as brain imaging and blood-based data, (3) associations to
family history / genetics, (4) characteristics during long-term follow-up, and (5) treatment
effects on cognition. In this way, the paper identifies knowledge gaps and suggests
recommendations for future research within each of the five areas. Based on the
current state of knowledge, we conclude that cognitive dysfunction does not qualify as
a diagnostic intermediate phenotype or endophenotype for bipolar disorder, although
promising new evidence points to emotion and reward processing abnormalities as
possible putative endophenotypes.
Keywords: cognition, cognitive dysfunction, bipolar disorder, unipolar disorder, schizophrenia, intermediate
phenotype, endophenotype
Cognitive dysfunction in bipolar disorder is a core illness symptom that has received intensive
research interest over the past decade because of its negative impact on socio-occupational
outcome, quality of life and illness prognosis (1–3). However, it is unclear whether patients’
cognitive deficits comprise a diagnostic intermediate phenotype that may aid diagnostic accuracy
and represent a key treatment target. The present perspective paper evaluates the present
evidence and discusses whether cognitive dysfunction in bipolar disorder qualifies as a diagnostic
intermediate phenotype using the Robin and Guze criteria of diagnostic validity (4) also concurrent
with the later endophenotype concept (5) and extended criteria suggestions (6). The rationale for
the Robin and Guze criteria was to develop criteria distinguishing between various psychiatric
disorders and aiming for a valid psychiatric classification system (4). An intermediate phenotype
was later defined as a measurable component along the pathway between disease and distal
genotype, and have emerged as an important concept in the study of complex neuropsychiatric
diseases (5). An endophenotype may be neurophysiological, biochemical, endocrinological,
neuroanatomical, cognitive, or neuropsychological in nature (5). The paper will review current
data on cognitive dysfunction within (1) delineation of the clinical intermediate phenotype, (2)
associations of the intermediate phenotype with para-clinical data such as brain imaging and
blood-based data, (3) associations to family history / genetics, (4) characteristics during long-term
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follow-up, and (5) treatment effects on cognition. Within each
of these five points, the specificity of the findings in relation
to bipolar disorder compared with schizophrenia and unipolar
disorder will be summarized. The paper will identify knowledge
gaps and suggest recommendations for future research within
each of the five areas.
DELINEATION AND CHARACTERIZATION
OF THE CLINICAL INTERMEDIATE
PHENOTYPE
This area concerns whether cognitive dysfunction in bipolar
disorder in remission is circumscribed clinically as a separate
diagnostic intermediate phenotype of bipolar disorder and
whether such an intermediate phenotype differs from similar
intermediate phenotypes within related disorders such as
schizophrenia and unipolar disorder.
Meta-analyses have consistently shown disturbances in
executive function, verbal learning and memory, visual memory
and attention in bipolar disorder compared with healthy control
individuals (7–10). Cognitive impairment in the remitted phase
of bipolar disorder is on average of a moderate effect size
(7), however, with a substantial cognitive heterogeneity: 12–
40% of patients present global cognitive impairments across
several domains, 29–40% show selective deficits in attention
and psychomotor speed, and 32–48% are relatively “cognitively
intact” in comparison with norms (11). Subgroups with
neurocognitive impairments present reduced functional capacity,
more stress and poorer quality of life than patients who are
cognitively intact, despite similar degrees of subsyndromal mood
symptoms (2, 11, 12). Compared with bipolar disorder type
II (hypomanic and depressive episodes; no manic episodes),
bipolar disorder type I (manic and/or depressive episodes)
seems to be associated with modestly more pronounced global
cognitive impairment as well as increased disturbances in
verbal memory, processing speed, executive function speed, and
executive function accuracy (13).
On the other hand, cognitive deviances are not specific for
bipolar disorder. Cognitive impairment is also prevalent in
schizophrenia (14) and unipolar disorder (15), and there is
no specific neuropsychological signature that can facilitate
the diagnostic differentiation between bipolar disorder,
schizophrenia, and unipolar disorder (16), notwithstanding,
neuropsychological deficits appear more severe in schizophrenia
(14, 17) and bipolar disorder (15). In schizophrenia and
bipolar disorder, cognitive impairments have been found to
correlate with socio-demographic (lower education and work
capacity), clinical (more hospitalizations, longer duration of
illness, negative psychotic symptoms, and non-remission status),
treatment (antipsychotics, anti-cholinergics) variables and
lower psychosocial functioning (1, 3, 18). Similar predictors of
cognitive dysfunction are found in unipolar disorder but with
more variable evidence, possibly because of the generally milder
cognitive impairments in this patient group (19, 20).
Emotion dysregulation may be another cognitive feature of
bipolar disorder that persists into periods of remission. Such
deficits in “hot” (emotional) cognition are closely linked to
emotional disturbances (21) and difficulties in socio-emotional
behavior and interpersonal relations in bipolar disorder (22). Hot
cognition abnormalities in bipolar disorder have been observed
within three domains; emotional processing, reward processing,
and emotion regulation [reviews in (23, 24)].
Emerging evidence points to partial persistence of such hot
cognition dysfunction during remission in unipolar disorder,
particularly within negative affect processing, (25) and the
presence of similar abnormalities in healthy relatives of
patients with unipolar disorder, at least at a neural level (25,
26). Hot cognition has not been systematically investigated
across mood disorders and schizophrenia although some data
point toward somewhat dissociable deficits in primary reward
processing in unipolar disorder and schizophrenia (27). A key
question remains whether deficits in experiencing rewards are
independent of anhedonia in schizophrenia and whether level
of observed reward disruption across unipolar disorder and
schizophrenia a is a matter of severity rather than reflecting
a qualitatively distinct mechanism (27). In contrast, a few
studies of patients with bipolar disorder found evidence for a
distinct positive bias in emotion processing and elevated reward
responsiveness (28)—cognitive features that may in the future aid
diagnostic discrimination between the disorders.
ASSOCIATIONS OF THE INTERMEDIATE
PHENOTYPE WITH PARA-CLINICAL DATA
SUCH AS BRAIN IMAGING AND
BLOOD-BASED DATA
It is unknown whether shared manifestations of cognitive
dysfunction across diagnostic categories also reflect shared
neurobiological mechanisms or whether the sources of
impairment differ. A recent study investigated the associations
between general cognitive deficits (non-emotional or so called
“cold”) and functional network integrity measures including
global and local efficiency of the whole brain, cingulo-opercular
network (CON), frontoparietal network, and auditory network
(29). Patients with schizophrenia and psychotic bipolar disorder
had significantly reduced CON global efficiency compared with
healthy controls (29). All patients with psychotic disorders had
significantly reduced CON local efficiency, but the clinical groups
did not differ from one another. The CON global efficiency was
significantly associated with general cognitive ability across
all groups and significantly mediated the association between
psychotic disorder status and general cognition. It was concluded
that these findings provide evidence that “reduced CON and
subcortical network efficiency may play a role in the general
cognitive deficit observed across the psychosis” (29).
Another common neural underpinning of cognitive deficits
across bipolar disorder, unipolar disorder, and schizophrenia
is aberrant task-related activity in the dorsal prefrontal cortex
(PFC), although findings regarding the direction of the aberrant
activity vary between studies withmost evidence for hypo-activity
in schizophrenia and bipolar disorder while the findings in
unipolar disorder are more variable. In particular, we found
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in a systematic review of >100 neuroimaging studies across
bipolar disorder and unipolar disorder consistent evidence for
abnormal (predominantly hypo-) activity in dorsal and lateral
PFC cognitive control regions during performance on working
memory, executive skills, memory encoding, and sustained
attention (Miskowiak and Petersen, in press). Notably, the
direction of this dorsal PFC activity depended on patients’
performance levels. Dorsal PFC hypo-activity is consistently
linked to impaired task performance; that is reduced cognitive
capacity. In contrast, dorsal PFC hyper-activity is generally
accompanied by normal performance levels and thus seems
to reflect reduced cortical efficiency; that is, a need to recruit
more neural resources to maintain normal performance. These
associations are likely to explain the more consistent evidence
for dorsal PFC hypo-activity in the generally more severely
cognitively impaired patients groups (i.e., schizophrenia and
bipolar disorder).
Another consistent finding in the review was reduced
deactivation of the default mode network (DMN) and limbic
structures during active task performance across bipolar disorder
and unipolar disorder (ibid). This suggests that cognitive
impairments across mood disorders are exacerbated by a
failure to suppress task-irrelevant neural activity associated with
emotional reactivity, self-focus and rumination (ibid).
Emerging neuroimaging evidence points to deficits in emotion
dysregulation being a prominent feature of bipolar disorder,
while unipolar disorder seems to be more consistently associated
with negative processing biases (30). Emotion dysregulation
in bipolar disorder seems associated with increased activity
in limbic regions implicated in emotion-generation paired
with deficient lateral prefrontal top-down control of emotional
responses (31). However, this finding is not specific to bipolar
disorder; indeed neuroimaging studies of social cognition
in patients with mood disorders have generally revealed
enhanced activation in limbic and emotion-related structures
and attenuated activity within frontal regions associated with
emotion regulation and higher cognitive functions. These results
reveal an “overall lack of inhibition by higher-order cognitive
structures on limbic and emotion-related structures during
social cognitive processing in patients with mood disorders”
(32). Critically, key variables, including illness burden, symptom
severity, comorbidity, medication status, and cognitive load may
moderate this pattern of neural activation (32).
Peripheral inflammation might be related to cognitive deficits
in schizophrenia and bipolar disorder. Single studies suggest
the role of C-reactive protein (CRP), interleukin (IL)-1 receptor
antagonist, IL-6, and tumor necrosis factor-α (TNF-α) with its
receptors in the development of cognitive impairment in bipolar
disorder as summarized in reviews (33, 34). Due to low number
of studies, it is difficult to draw conclusions on the involvement
of CRP and cytokine alterations in the development of cognitive
deficits in bipolar disorder. More consistent results indicate
worse cognitive performance in schizophrenia patients with
higher CRP levels (33). Evidence for the involvement of other
cytokines in cognitive impairment in patients with schizophrenia
is less convincing due to discordant results and scarcity of
studies (33). Nevertheless, a larger study found that general
cognitive abilities may be associated with IL-1Ra and sTNF-R1
in schizophrenia and with soluble CD40 ligand (sCD40L) and
IL-1Ra in bipolar disorder patients (35).
ASSOCIATIONS TO FAMILY HISTORY /
GENETICS
A recent meta-analysis of cognitive functions in first-degree
relatives of probands with bipolar disorder and schizophrenia
showed that probands with schizophrenia displayed cognitive
deficits in all domains (d = 0.20–0.58) whereas probands with
bipolar disorder underperformed healthy controls in processing
speed, verbal fluency and speed based executive function
tests (36). It was concluded that “inefficiency in processing
information and impaired processing speed might be common
vulnerability factors for major psychoses.” On the other hand,
“low performance in accuracy based tasks and deficits in general
intellectual ability, verbal learning, planning, and working
memory might be more specifically associated with risk for
schizophrenia” (36). Further, we found in a systematic review of
neuroimaging studies of healthy first-degree relatives of patients
with bipolar disorder emerging evidence for abnormalities in
emotional processing—and regulation and reward processing
being candidate endophenotypes (37). We investigated this
notion in a cohort of monozygotic twins at risk of either
unipolar or bipolar disorder (reflected by a co-twin history of
that disorder) (38). Interestingly, we found that twins at risk
of bipolar disorder showed increased sensitivity and reactivity
to positive social stimuli in comparison with individuals at
risk of unipolar disorder and low-risk control twins. Together,
these findings provide emerging evidence for positive bias being
a putative neurocognitive endophenotype that is specific for
bipolar disorder.
In terms of neurocognitive-genetic investigations, catechol-
O-methyltransferase (COMT) and brain-derived neurotrophic
factor (BDNF) are the two most studied candidate genes
especially in patients with schizophrenia (39). Whereas BDNF
Val66Met carriers seem to perform worse on verbal working
memory, problem solving, and visuo-spatial abilities, COMT
Val158Met carriers may perform better in working memory,
attention, executive functioning with evidence of genotype
by diagnosis interactions including high-risk individuals (39),
although findings are not uniform (40, 41). In terms of genetic-
structural MRI studies, “patients with schizophrenia are found
to have reductions in the frontal, temporal, parietal cortices,
and limbic regions, which are associated with BDNF, COMT,
and neuregulin-1 (NRG1) genes” (39). Genetic-functional MRI




Cognitive deficits in bipolar disorder in remission seem to
persist over time or even progress supporting the view that
these deficits qualify for an intermediary phenotype. Using
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a 5 years longitudinal cohort, 91 individuals with bipolar
disorder and 17 healthy controls were administered a battery
of neuropsychological tests that captured four main areas of
executive functioning that were found to persist over time (43).
Based on cross-sectional studies, cognitive deficits seem to
deteriorate during late stages of the disorder (44). In contrast,
there is a lack of longitudinal studies on cognition in bipolar
disorder (45, 46) with the largest study being the study by Ryan
et al. (43, 47). A new meta-analysis comparing short-term (mean
of 1.5 years) and long-term (mean of 5.5 years) neurocognitive
changes in 643 euthymic patients with bipolar disorder, 367
healthy controls and 168 patients with schizophrenia found no
cognitive changes over time in any of the three cohorts (46).
Besides the small sample sizes in each study, limitations included
short follow-up (mean follow-up period of 4.6 years) specifically
for studies of bipolar disorder, high attrition rates (up to 45%)
among all participants and strict euthymia criteria for bipolar
patients included in the analyses, which may have introduced
a selection bias (including only the high functioning patients),
as also concluded in a prior similar meta-analysis of bipolar
disorder (48).
Regarding cognitive functioning in unipolar disorder, some
cross-sectional studies suggest that cognitive function in the
euthymic phase is associated with the duration or number of
prior episodes [(49–54), for a review see: (19)].
Studies on the risk of developing dementia in unipolar
disorder and bipolar disorder have recently been summarized
(55). It was concluded that a meta-analysis including 44 studies
on depression and six on bipolar disorder (56) as well as all
subsequent studies have confirmed that unipolar disorder (56–
60) and bipolar disorder (56–58, 60, 61) are associated with
increased risks of developing dementia long-term (as a clinical
diagnosis). It was further concluded that longitudinal studies
of bipolar disorder may have had to short follow-up time
(mean follow-up period of 4.62 years) to reveal a decrease in
neuropsychological functioning over time in contrast to the much
longer follow-up time in studies with dementia as the outcome
measure (55).
TREATMENT EFFECTS ON COGNITION
A recent systematic review on novel pharmacological (N-acetyl
cysteine, pregnolone, ketamine and pramipexole, mifepristone,
galantamine, insulin, erytrophoietin, withania somnifera, and
citicoline) and psychological treatments (cognitive remediation
and cognitive training) on cognition in bipolar disorder
identified 19 studies of which 13 were RCTs and six were
open-label or non-randomized studies (62). The efficacy on
cognition was overall disappointing or preliminary, possibly due
to several methodological challenges. Similarly, a later controlled
trial found no effect of methylene blue on cognition in bipolar
disorder (63). Among the most promising pharmacological
treatments for cognitive dysfunction across bipolar disorder and
unipolar disorder is erythropoietin, but the evidence is still
preliminary (62, 64). These findings are partly in accordance with
findings within unipolar disorder and schizophrenia with only a
few studies have shown benefit for pharmacological treatments
(64–66) and with a lack of successful replication of these data (64,
66, 67). However, psychological treatment programs involving
intensive cognitive remediation have revealed more consistent
positive effects on cognition in schizophrenia (68, 69) and
emerging evidence in mood disorders (64, 70).
CONCLUSION AND RECOMMENDATIONS
FOR FUTURE RESEARCH
It is clear from the present summary of studies on cognition in
bipolar disorder that at the current state of knowledge cognition
in bipolar disorder does not qualify as a diagnostic intermediate
phenotype using the Robin and Guze criteria of diagnostic
validity (4) or the later endophenotype concept (5, 6), although
emerging evidence points to hot cognition abnormalities
representing promising putative endophenotypes. Rather, extant
findings within four of the five Robin and Guze criteria
generally support the dimensional hypothesis that a shared
neurobiological mechanism underlies cognitive impairment
across bipolar disorder, unipolar disorder and schizophrenia:
(1) there may not be a specific neuropsychological signature
that differentiate cognitive deviances in bipolar disorder from
those in schizophrenia and unipolar disorder (only potentially
within hot cognition); (2) brain imaging or blood-based data
does not at the current state of knowledge differentiate between
cognitive dysfunction in bipolar disorder, schizophrenia or
unipolar disorder; (3) probands to patients with bipolar disorder,
schizophrenia, and unipolar disorder show similar cognitive
deficits although with varying severity, except for within hot
cognition. Investigations of genetic associations to cognitive
deviances are in its early stages, only (4) treatment effects of
pharmacological or psychological interventions on cognition do
not seem to differ within bipolar disorder, schizophrenia and
unipolar disorder. The fourth Robin and Guze criterion seems
fulfilled as cognitive deficits in bipolar disorder seem either stable
over time or progress during long-term supporting cognitive
deficits as an intermediary phenotype.
It is further evident from the present summary of studies on
cognition in bipolar disorder that a number of research initiatives
are needed within all five of the Robin and Guze criteria.
1. Research is needed integrating “hot” and “cold” cognition
in bipolar disorder. Few if any studies have investigated how
emotion dysregulation (i.e., hot cognition) interact with cold
cognition. As recently emphasized, cognitive biases, reward
processing and motivation, rumination, and mood stability may
play significant roles in the manner in which attention, appraisal,
and response processes are deployed in mood disorders (71).
2. Emotion dysregulation (hot cognition) should be
investigated across mood disorders and schizophrenia. Emotion
dysregulation has emerged as a new research area that may
characterize mood disorders, and potentially specifically
bipolar disorder, rather than schizophrenia. Although these
speculations are clinically plausible, emotion dysregulation has
not been systematically investigated across mood disorders and
schizophrenia.
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3. Structural and functional neuroimaging data on cognitive
features (“cold” and “hot”) should be integrated across mood
disorders. Such multimodal neuroimaging studies aiming to
identify structure-function relationships in neural circuitry have
previously been suggested in relation to bipolar disorder in
general (24). As highlighted, a very small number of studies
examined structure-function relationships in prefrontal cortical-
amygdala circuitry in adults with bipolar disorder type I
and bipolar disorder type II (24). We suggest integrating
investigations of “cold” and “hot” cognitive features into the loop
and across mood disorders.
4. Neurogenetics should be integrated into research in
cognitive disturbances in patients with mood disorders and
schizophrenia and in their first degree relatives.
5. Research in cognitive enhancement treatments. We have
previously suggested implementation of a ‘neurocircuitry-based’
biomarker model to evaluate neural target engagement in
cognitive enhancement (62). We suggest that a valid biomarker
model for cognitive improvement must fulfill five key validity
criteria: it must (i) be sensitive to a treatment with pro-cognitive
effects, (ii) produce similar effects in patients with cognitive
dysfunction and healthy participants, (iii) be sensitive to effective
treatments with different neurochemical mechanisms, (iv) be
unresponsive to ineffective treatments, and (v) be sensitive to
both cognitive improvement and—decline. A potential solution
to the problem is a step-wise approach with which we: (i) identify
the most reliable functional neuronal correlates of cognitive
deficits in neuropsychiatric disorders, (ii) select one of the most
promising candidate treatments and test its ability to modulate
the activity in these dysfunctional neural circuitries in a short-
term proof-of-concept fMRI study, and (iii) if target engagement
is shown in (ii), then test the effects of this candidate treatment
in a longer-term clinical phase 2 trial in patients using fMRI
to elucidate the neuronal changes underlying potential pro-
cognitive effects.
More evidence is needed confirming whether cognitive
deficits comprise a diagnostic intermediate phenotype in bipolar
disorder. The long-term perspective is that cognitive deficits may
aid diagnostic accuracy and represent a key treatment target in
bipolar disorder.
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